Q1 2023 13F Holders as of 3/31/2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
61.8M
-
Number of holders
-
69
-
Total 13F shares, excl. options
-
39.8M
-
Shares change
-
-1.46M
-
Total reported value, excl. options
-
$310M
-
Value change
-
-$11.1M
-
Put/Call ratio
-
0
-
Number of buys
-
32
-
Number of sells
-
-26
-
Price
-
$7.79
Significant Holders of Monte Rosa Therapeutics, Inc. - COMMON STOCK (GLUE) as of Q1 2023
78 filings reported holding GLUE - Monte Rosa Therapeutics, Inc. - COMMON STOCK as of Q1 2023.
Monte Rosa Therapeutics, Inc. - COMMON STOCK (GLUE) has 69 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.8M shares
of 61.8M outstanding shares and own 64.32% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (7.69M shares), FMR LLC (6.42M shares), Avoro Capital Advisors LLC (4.33M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.69M shares), BlackRock Inc. (3.61M shares), Cormorant Asset Management, LP (2.89M shares), T. Rowe Price Investment Management, Inc. (1.72M shares), Aisling Capital Management LP (1.47M shares), Alphabet Inc. (1.46M shares), and VANGUARD GROUP INC (1.45M shares).
This table shows the top 69 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.